Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Wang S, Yin H, Huang Y, Guan X
Additional information Third-party verified by MZ Biolabs (Tucson, AZ), a US DEA Schedule III licensed facility (License: RP0584676)
The FDA approved Foundayo on April 1, 2026, for adults with obesity (BMI of 30 or higher) or adults with overweight (BMI of 27 or higher) who have at least one weight-related health condition, addressing a population where 40.3% of US adults have obesity
Important Note on the Evidence Base Important note on the evidence base: The peer-reviewed IGF-1 LR3 research literature consists of in vitro characterization studies (receptor binding, IGFBP interaction, cell-culture potency) and a small body of rodent in vivo work primarily in cachexia and protein-metabolism models
Alternatively, consider injectable semaglutide to avoid the absorption conflict entirely
Probst, L
